Literature DB >> 9022611

Effects of cancer on spermatozoa quality after cryopreservation: a 12-year experience.

O F Padron1, R K Sharma, A J Thomas, A Agarwal.   

Abstract

OBJECTIVE: To determine whether type of cancer and response to treatment was related to prefreeze or post-thaw semen quality and to predict post-thaw sperm motility from prefreeze motility.
DESIGN: Retrospective study.
SETTING: Tertiary care institution. PATIENT(S): One hundred six cancer patients cryopreserving their semen specimens. INTERVENTION(S): Computer-assisted semen analysis was performed before and after cryopreservation on each patient specimen. MAIN OUTCOME MEASURE(S): The relationship of sperm motility and motion characteristics to type of cancer and patient's response to treatment. RESULT(S): Prefreeze and post-thaw semen quality did not differ between patients presenting with testicular cancer and Hodgkin's disease. Patients with leukemia or advanced soft tissue cancer had a higher prefreeze and post-thaw motility and higher total and motile sperm count than testicular and Hodgkin's disease patients. A prefreeze sperm motility of > or = 15% could predict a post-thaw motility of > 10%. CONCLUSION(S): Prefreeze or post-thaw semen quality in cancer patients is not affected (except the prefreeze motile sperm count within the testicular cancer patients) by the type of disease. Prefreeze motility can predict post-thaw motility. Cryopreservation of semen should be offered to cancer patients irrespective of the type of disease.

Entities:  

Mesh:

Year:  1997        PMID: 9022611     DOI: 10.1016/S0015-0282(97)81919-X

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  15 in total

Review 1.  Effects of cancer and anti-neoplastic treatment on the human testicular function.

Authors:  A De Palma; E Vicari; I Palermo; R D'Agata; A E Calogero
Journal:  J Endocrinol Invest       Date:  2000-11       Impact factor: 4.256

2.  Congruence of reproductive concerns among adolescents with cancer and parents: pilot testing an adapted instrument.

Authors:  Gwendolyn P Quinn; Caprice Knapp; Devin Murphy; Kelly Sawczyn; Leonard Sender
Journal:  Pediatrics       Date:  2012-03-19       Impact factor: 7.124

3.  Characteristics of cryopreserved semen from men with lymphoma.

Authors:  J Hallak; A M Mahran; A Agarwal
Journal:  J Assist Reprod Genet       Date:  2000-11       Impact factor: 3.412

4.  The effects of cryopreservation on semen from men with sarcoma or carcinoma.

Authors:  J Hallak; A Mahran; J Chae; A Agarwal
Journal:  J Assist Reprod Genet       Date:  2000-04       Impact factor: 3.412

5.  The provision of a semen cryopreservation service for male cancer sufferers in the Republic of Ireland.

Authors:  D Keane; S Naughton; K Waite; R F Harrison
Journal:  Ir J Med Sci       Date:  2000 Jan-Mar       Impact factor: 1.568

6.  [Cryopreserved human sperm deposits: usability after decades of storage].

Authors:  M Bolten; L Weissbach; R Kaden
Journal:  Urologe A       Date:  2005-08       Impact factor: 0.639

7.  Sperm banking and assisted reproductive outcome in men with cancer: a 10 years' experience.

Authors:  Thomas Freour; Sophie Mirallie; Miguel Jean; Paul Barriere
Journal:  Int J Clin Oncol       Date:  2011-10-07       Impact factor: 3.402

Review 8.  Fertility preservation and management of gonadal failure associated with lymphoma therapy.

Authors:  Simon J Howell; Stephen M Shalet
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  Successful spouse pregnancy of male patients with severe aplastic anemia and chronic myelogenous leukemia using spermatozoa banked prior to bone marrow transplantation and using the ICSI procedure: case reports.

Authors:  Sung-Won Cho; Sook-Hwan Lee; Mi-Kyung Chung; Hyun-Ah Kim; Hyung-Min Chung; Yun-Jung Lee; Hwang Kwon; Tae-Ki Yoon; Kwang-Yul Cha
Journal:  J Assist Reprod Genet       Date:  2004-02       Impact factor: 3.412

Review 10.  Fertility preservation in the male with cancer.

Authors:  Daniel H Williams
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.